| Literature DB >> 21507212 |
Anita Kotwani1, Kathleen Holloway.
Abstract
BACKGROUND: The overall volume of antibiotic consumption in the community is one of the foremost causes of antimicrobial resistance. There is much ad-hoc information about the inappropriate consumption of antibiotics, over-the-counter availability, and inadequate dosage but there is very little actual evidence of community practices.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21507212 PMCID: PMC3097160 DOI: 10.1186/1471-2334-11-99
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Percent of prescriptions with various classes of antibiotics in the facilities surveyed in Delhi, India (December 2007-November 2008)
| Antibiotics | Public sector | Private retail pharmacies | Private clinics |
|---|---|---|---|
| Cephalosporins | 5.7% | 14.4% | 11.6% |
| Flouroquinolones | 9.0% | 11.1% | 13.7% |
| Penicillins | 10.2% | 8.8% | 8.7% |
| Macrolides | 6.6% | 4.0% | 3.8% |
| Tetracyclines | 3.4% | 0.6% | 2.2% |
| Co-trimoxazole | 4.4% | 0.3% | 2.6% |
| Aminoglycosides | - | 0.3% | 0.8% |
Antibiotic use (DDD/ 1000 patients) in the facilities surveyed in Delhi, India (December 2007-November 2008)
| Antibiotic name | Public sector | Private retail | Private clinic | |||
|---|---|---|---|---|---|---|
| DDD | %* | DDD | %* | DDD | %* | |
| Cefuroxime | 3132 | 7.2% | 13511 | 10.8% | 8987 | 11.0% |
| Cephalexin | 971 | 2.2% | ||||
| Cefixime | - | 8065 | 6.4% | 5919 | 7.3% | |
| Cefixime + clavulanic acid | - | 4127 | 3.3% | 2897 | 3.5% | |
| Others | 31 | 7256 | 3635 | |||
| Subtotal | ||||||
| Ofloxacin | 5516 | 12.7% | 15652 | 12.5% | 13222 | 16.2% |
| Ciprofloxacin | 4367 | 10.1% | 7557 | 6.0% | 5434 | 6.7% |
| Levofloxacin | - | 5559 | 4.4% | 4586 | 5.6% | |
| Norfloxacin | 2590 | 6.0% | 3332 | 2.6% | 1028 | 1.3% |
| Others | 86 | 5639 | 2750 | |||
| Subtotal | ||||||
| Amoxicillin | 6403 | 14.7% | 8240 | 6.6% | 2263 | 2.8% |
| Amoxicillin+Calvulinic acid | 2873 | 6.6% | 16299 | 13.0% | 14370 | 17.6% |
| Amoxicillin+Cloxacillin | - | 4082 | 3.2% | 3065 | 3.8% | |
| Ampicillin | 2234 | 5.1% | ||||
| Others | 1078 | 1859 | 148 | |||
| Subtotal | ||||||
| Roxithromycin | 3995 | 9.2% | 6836 | 5.4% | 3353 | 4.1% |
| Azithromycin | 38 | 0.09% | 5404 | 4.3% | 3648 | 4.5% |
| Erythromycin | 2286 | 5.3% | 2535 | 2.0% | 292 | 0.3% |
| Others | 0 | 801 | 719 | |||
| Subtotal | ||||||
| Doxicycline | 4210 | 9.7% | 6147 | 4.9% | 4440 | 5.4% |
| Tetracycline | 1759 | 4.0% | 949 | 0.8% | 7 | 0.008% |
| Others | 15 | 12 | 33 | |||
| Subtotal | ||||||
| Cotriamoxazole | 4.0% | 1.3% | 0.2% | |||
*% of total DDDs/1000 patients for all antibiotics
Figure 1Monthly use of cephalosporins in the community from December 2007-November 2008.
Figure 2Monthly use of fluoroquinolones in the community from December 2007-November 2008.
Figure 3Monthly use of penicillins in the community from December 2007-November 2008.
Figure 4Monthly use of macrolides in the community from December 2007-November 2008.
Figure 5Monthly use of cotrimoxazole in the community from December 2007-November 2008.
Figure 6Monthly use of tetracyclines in the community from December 2007-November 2008.